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Guillain–Barré syndrome (GBS) is an inflammatory 
disease of the PNS and is the most common cause of 
acute flaccid paralysis, with an annual global incidence 
of approximately 1–2 per 100,000 person- years1. GBS 
occurs more frequently in males than in females and 
the incidence increases with age, although all age groups 
can be affected1. Patients with GBS typically present with 
weakness and sensory signs in the legs that progress 
to the arms and cranial muscles, although the clinical 
presentation of the disease is heterogeneous and several 
distinct clinical variants exist. Diagnosis of GBS is based 
on the patient history and neurological, electrophysio-
logical and cerebrospinal fluid (CSF) examinations2–4. 
Other diseases that have a similar clinical picture to 
GBS must be ruled out4. Electrophysiological studies 
provide evidence of PNS dysfunction and can distin-
guish between the subtypes of GBS: acute inflammatory 
demyelinating polyradiculoneuropathy (AIDP), acute 
motor axonal neuropathy (AMAN) and acute motor 
sensory axonal neuropathy (AMSAN)5. Disease pro-
gression can be rapid, and most patients with GBS reach 
their maximum disability within 2 weeks. About 20% of 
patients with GBS develop respiratory failure and require 
mechanical ventilation. Cardiac arrhythmias and blood 
pressure instability can occur owing to involvement 
of the autonomic nervous system6. This involvement of 
the autonomic nervous system contributes to mortal-
ity, which is estimated at 3–10% for patients with GBS 
even with the best medical care available7–9. After the 
initial progressive phase, patients with GBS reach a pla-
teau phase that can last from days to weeks or months, 
after which they start to recover, and 60–80% of patients 
with GBS are able to walk independently 6 months after 
disease onset, with or without treatment10,11. GBS is a 
monophasic illness, although some patients can deteri-
orate after first stabilizing or improving on therapy — a 
phenomenon that is referred to as a treatment- related 
fluctuation (TRF). Relapses of GBS can occur in 2–5% 
of patients10,12–15.
GBS is thought to be caused by an aberrant immune 
response to infections that results in damage to periph-
eral nerves, although the pathogenesis is not fully 
understood. In a subgroup of patients with GBS, serum 
antibodies are found against gangliosides, which reside 
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at high densities in the axolemma and other compo-
nents of the peripheral nerves16,17. Complement activa-
tion, infiltration of macrophages and oedema are typical 
characteristics of affected peripheral nerves and nerve 
roots in patients with GBS16.
The incidence of GBS can increase during outbreaks 
of infectious illnesses that trigger the disease18. Most 
recently, the Zika virus epidemics in French Polynesia 
in 2013 and in Latin America and the Caribbean in 
2015–2016 were linked to an increase in individuals 
being diagnosed with GBS19–21.
The Zika virus outbreaks brought to light the lack 
of globally applicable guidelines for the diagnosis and 
management of GBS. Such guidelines are necessary 
because the diagnosis of GBS can be challenging owing 
to heterogeneity in clinical presentation, an extensive 
differential diagnosis, and the lack of highly sensitive 
and specific diagnostic tools or biomarkers. Guidance 
for the treatment and care of patients with GBS is also 
needed because disease progression can vary greatly 
between patients, which complicates an entirely pre-
scriptive approach to management. In addition, treat-
ment options are limited and costly, and many patients 
experience residual disability and complaints that can be 
difficult to manage.
Availability of globally applicable clinical guide-
lines for GBS is especially important as new outbreaks 
of pathogens that trigger GBS are likely to occur in 
the future. To generate this globally applicable clinical 
guideline for GBS, the ten most important steps in the 
management of GBS, covering diagnosis, treatment, 
monitoring, prognosis and long- term management, 
were identified by a group of international experts 
on GBS (Fig. 1). For each step, recommendations were 
provided on the basis of evidence from the literature 
and/or expert opinion, and consensus was sought for 
each recommendation to finalize the guideline. These 
recommendations are intended to assist providers in 
clinical decision- making; however, the use of the infor-
mation in this article is voluntary. The authors assume 
no responsibility for any injury or damage to persons 
or property arising out of or related to any use of this 
information, or for any errors or omissions.
Methods
Following the outbreak of Zika virus and its associ-
ation with an increase in the incidence of GBS, the 
European Union- funded Zika Preparedness Latin 
American Network (ZikaPLAN) was established22. Our 
new guideline was initially prepared by participants of 
the ZikaPLAN network, comprising experts on GBS 
from the Netherlands (S.E.L., M.R.M. and B.C.J.), Brazil 
(F.d.A.A.G. and M.E.D.) and the United Kingdom 
(H.J.W.). These members brought specific clinical and 
research expertise to the guideline from their leading 
roles in large international projects on GBS (such as the 
International GBS Outcome Study (IGOS)), along with 
direct experience in managing the large increases in GBS 
cases in Zika virus- affected regions of Latin America23. 
To develop the preliminary guidelines, a series of in- person 
meetings were held between lead authors on the writing 
committee (S.E.L., M.R.M., B.C.J. and H.J.W.), along with 
smaller individual meetings with colleagues in Latin 
America (S.E.L., F.d.A.A.G. and M.E.D.) and continuous 
e- mail correspondence to review drafts and receive 
input. On the basis of their expert opinion and through 
consensus, this group identified ten of the most important 
steps in the diagnosis and management of GBS.
For each step, structured literature searches were per-
formed in October 2018 by members of the writing com-
mittee (S.E.L and M.R.M), using PubMed and Embase, 
and the results of these searches provided the basis for 
the first draft of the guideline. The main inclusion crite-
rion for the literature searches was any study, trial, review 
or case report published from 2015 onwards that pro-
vided detail on the diagnosis, treatment, manage ment 
or prognosis of patients with GBS. Publications on the 
pathogenesis of GBS, or those with a focus on diseases 
not related to GBS, along with publications written in 
Key points
•	Classic Guillain–Barré syndrome (GBS) is an acute- onset ascending sensorimotor 
neuropathy, but the disease can present atypically or as a clinical variant.
•	Abnormal results in electrophysiological studies and a combination of an increased 
protein level and normal cell count in cerebrospinal fluid are classic features of GBS, 
but patients with GBS can have normal results in both tests, especially early in the 
disease course.
•	Respiratory function should be monitored in all patients as respiratory failure can 
occur without symptoms of dyspnoea.
•	Intravenous immunoglobulin and plasma exchange are equally effective in treating 
GBS; no other treatments have been proven to be effective.
•	The efficacy of repeat treatment in patients who have shown insufficient clinical 
response is uncertain; nevertheless, this practice is common in patients who show 
deterioration after an initial treatment response.
•	Clinical improvement is usually most extensive in the first year after disease onset and 
can continue for >5 years.
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Diagnosis
Long-term care
Acute care
   When to suspect GBS
• Rapidly progressive bilateral limb weakness 
and/or sensory deficits
• Hypo/areflexia
• Facial or bulbar palsy
• Ophthalmoplegia and ataxia
1     How to diagnose GBS
• Check diagnostic criteria 
• Exclude other causes 
• Consider: 
• Routine laboratory tests 
• CSF examination 
• Electrophysiological studies
2
    Predicting outcome
• Calculate mEGOS on admission 
• Recovery can continue >3 years after onset 
• Recurrence is rare (2–5%)
9     Rehabilitation
• Start rehabilitation programme early 
• Manage long-term complaints: fatigue, pain and 
psychological distress 
• Contact GBS patient organizations
10
    When to admit to ICU
One or more: 
• Rapid progression of weakness 
• Severe autonomic or swallowing dysfunction 
• Evolving respiratory distress 
• EGRIS >4
3     When to start treatment
One or more: 
• Inability to walk >10 m independently 
• Rapid progression of weakness 
• Severe autonomic or swallowing dysfunction 
• Respiratory insufficiency
4
    Clinical progression
Treatment-related fluctuation:
• Repeat same treatment
No initial response or incomplete recovery:
• No evidence for repeating treatment
8
    Treatment options
• Intravenous immunoglobulin (0.4 g/kg daily for 5 days) 
• Plasma exchange (200–250 ml/kg for 5 sessions)
5
    Early complications
• Choking 
• Cardiac arrhythmias 
• Infections 
• Deep vein thrombosis 
• Pain 
• Delirium 
• Depression 
• Urinary retention
• Constipation
• Corneal ulceration 
• Dietary deficiency 
• Hyponatraemia
• Pressure ulcers 
• Compression neuropathy 
• Limb contractures
7
    Monitoring
Regularly assess:* 
• Muscle strength 
• Respiratory function 
• Swallowing function 
• Autonomic function 
• Blood pressure 
• Heart rate/rhythm 
• Bladder/bowel control
6
Fig. 1 | Ten- step approach to the diagnosis and management of Guillain–Barré syndrome. This bullet point summary 
provides an overview of each of the ten steps described in the guideline. *Frequency of monitoring is dependent on the 
clinical picture and should be assessed in individual patients. CSF, cerebrospinal fluid; EGRIS, Erasmus GBS Respiratory 
Insufficiency Score (Box 3); GBS, Guillain- Barré syndrome; ICU, intensive care unit; mEGOS, modified Erasmus GBS 
Outcome Score (Supplementary Table 3).
a language other than English or Dutch were excluded 
from the review. Keywords used in the search strategy 
included the following Medical Subject Headings (MeSH) 
terms: “Guillain–Barré syndrome” AND [“diagno sis” OR 
“therapeutics” OR “treatment outcome” OR “pro gnosis”]. 
To obtain literature for more specific topics, additional 
MeSH terms were combined with primary search key-
words, including “intravenous immuno globulins”, 
“plasma exchange”, “intensive care units”, “pregnancy”, 
“Miller Fisher syndrome” and “HIV”. Following this 
review of the most recent literature, landmark studies 
published prior to 2015 were identified for inclusion 
by the writing committee (S.E.L., M.R.M., B.C.J. and 
H.J.W.), along with additional papers selected by screen-
ing the reference lists of already included manuscripts 
and consultation with the authors. Where possible, our 
recommendations regarding treatment were based on 
systematic reviews. Expert opinion from the authors 
was sought for recommendations when more limited 
evidence (for example, cohort studies or case–control 
studies) was available, for instance on topics regarding 
the differential diagnosis or rehabilitation of GBS.
In consideration of the global variation in health-
care context and variants of GBS, this first draft was 
subsequently reviewed by an international group 
of experts on GBS from Argentina (R.R.), Australia 
(E.M.Y.), Bangladesh (B.I.), Brazil (M.L.B.F. and C.S.), 
China (Y.W.), Colombia (C.A.P.), Japan (S.K.), Malaysia 
(N.S.), the Netherlands (P.A.v.D.), Singapore (T.U.), 
South Africa (K.B.), the United States (D.R.C. and J.J.S.) 
and the United Kingdom (R.A.C.H). In total, seven 
rounds of review were held to reach a consensus. To 
consider the perspective of patients with GBS on the 
management of the disease, the GBS/CIDP Foundation 
International, a non- profit organization that provides 
support, education, research funding and advocacy to 
patients with GBS or chronic inflammatory demyelinat-
ing poly neuropathy (CIDP) and their families, reviewed 
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the manuscript and provided comment during the 
development of the guideline.
Step 1: when to suspect GBS
Typical clinical features
GBS should be considered as a diagnosis in patients 
who have rapidly progressive bilateral weakness of the 
legs and/or arms, in the absence of CNS involvement or 
other obvious causes. Patients with the classic sensori-
motor form of GBS present with distal paraesthesias 
or sensory loss, accompanied or followed by weakness 
that starts in the legs and progresses to the arms and 
cranial muscles. Reflexes are decreased or absent in 
most patients at presentation and in almost all patients 
at nadir10,24. Dysautonomia is common and can include 
blood pressure or heart rate instability, pupillary dys-
function, and bowel or bladder dysfunction25. Pain is 
frequently reported and can be muscular, radicular or 
neuropathic26. Disease onset is acute or subacute, and 
patients typically reach maximum disability within 
2 weeks11. In patients who reach maximum disability 
within 24 h of disease onset or after 4 weeks, alternative 
diagnoses should be considered2,3. GBS has a mono-
phasic clinical course, although TRFs and relapses occur 
in a minority of patients12,13.
Atypical clinical presentation
GBS can also present in an atypical manner. Weakness 
and sensory signs, though always bilateral, can be 
asymmetrical or predominantly proximal or distal, and 
can start in the legs, the arms or simultaneously in all 
limbs6,26. Furthermore, severe and diffuse pain or iso-
lated cranial nerve dysfunction can precede the onset 
of weakness26. Young (<6 years old) children in par-
ticular can present with nonspecific or atypical clinical 
Classic
sensorimotor
Pure motor
Motor symptoms Sensory symptoms Decreased consciousness Ataxia
Paraparetic Pharyngeal–
cervical–brachial
Bilateral facial palsy
with paraesthesias
Pure sensory Miller Fisher
syndrome
Bickerstaff brainstem
encephalitis
Fig. 2 | Pattern of symptoms in variants of Guillain–Barré syndrome. Graphic representation of the pattern of 
symptoms typically observed in the different clinical variants of Guillain–Barré syndrome (GBS). Symptoms can be  
purely motor, purely sensory (rare) or a combination of motor and sensory. Ataxia can be present in patients with Miller  
Fisher syndrome and both decreased consciousness and ataxia can be present in patients with Bickerstaff brainstem 
encephalitis. Symptoms can be localized to specific regions of the body , and the pattern of symptoms differs between 
variants of GBS. Although bilateral facial palsy with paraesthesias, the pure sensory variant and Miller Fisher syndrome  
are included in the GBS spectrum, they do not fulfil the diagnostic criteria for GBS. Adapted with permission from reF.113, 
©2019 BMJ Publishing Group Limited. All rights reserved.
features, such as poorly localized pain, refusal to bear 
weight, irritability, meningism, or an unsteady gait27,28. 
Failure to recognize these signs as an early presentation of 
GBS might cause delay in diagnosis28. In a minority 
of patients with atypical GBS, particularly those with 
only motor signs (pure motor variant) and an AMAN 
subtype on electrophysiological examination, normal or 
even exaggerated reflexes might be observed throughout 
the disease course29.
Variants
Some patients have a distinct and persistent clinical var-
iant of GBS that does not progress to the classic pattern 
of sensory loss and weakness. These variants include: 
weak ness without sensory signs (pure motor variant); 
weakness limited to the cranial nerves (bilateral facial 
palsy with paraesthesias), upper limbs (pharyngeal– 
cervical–brachial weakness) or lower limbs (paraparetic 
variant); and the Miller Fisher syndrome (MFS), which 
in its full manifestation consists of ophthalmoplegia, are-
flexia and ataxia6,30,31 (Fig. 2 and TaBle 1). In general, GBS 
variants are rarely ‘pure’ and often overlap in part with 
the classic syndrome or show features that are typical of 
other variant forms32.
Besides the variants listed above, pure sensory ataxia, 
Bickerstaff brainstem encephalitis (BBE) and a pure 
sensory variant are often included in the GBS spectrum 
because they share clinical or pathophysiological fea-
tures with GBS. However, the inclusion of these clinical 
variants is subject to debate as they do not fulfil the diag-
nostic criteria for GBS2,3,31 (Box 1). The pure sensory vari-
ant shares clinical features with the classic sensorimotor 
form of GBS, with the exception of the presence of motor 
symptoms and signs31,33; pure sensory ataxia and MFS 
have overlapping clinical profiles, and patients with BBE 
674 | NovemBeR 2019 | volume 15 www.nature.com/nrneurol
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usually present with symptoms resembling MFS and 
subsequently develop signs of brainstem dysfunction, 
including impaired consciousness and pyramidal tract 
signs30–32,34–36. Similar to patients with MFS, individuals 
with sensory ataxia or BBE can exhibit IgG antibodies to 
GQ1b or other gangliosides in their serum30,34. However, 
whether pure sensory GBS, pure sensory ataxia and 
BBE are variants of GBS and/or an incomplete form of 
MFS is subject to debate, and careful diagnostic work- 
up is required when these variants are suspected31,33,35 
(Boxes 1 and 2).
Preceding events
About two- thirds of patients who develop GBS report 
symptoms of an infection in the 6 weeks preceding the 
onset of the condition11. These infections are thought 
to trigger the immune response that causes GBS6. 
Six pathogens have been temporally associated with 
GBS in case–control studies: Campylobacter jejuni, 
cytomegalovirus, hepatitis E virus, Mycoplasma pneu-
moniae, Epstein–Barr virus and Zika virus18,20,37. It has 
been suggested that other pathogens are linked to GBS 
on the basis of evidence from case series or epidemio-
logical studies, but their role in the pathogenesis of GBS 
is uncertain38–43. In general, the absence of an antecedent 
illness does not exclude a diagnosis of GBS, as puta-
tive infections or other immunological stimuli can be 
subclinical.
Vaccines were first linked to GBS in 1976 when 
a 7.3-fold increase in the risk of GBS was observed 
among nonmilitary individuals in the United States 
who had received the ‘swine’ influenza vaccine44. The 
epidemi ological link between other vaccines and GBS 
has been examined many times since, but only two 
Table 1 | Variants of Guillain–Barré syndrome
Variant Frequency (% 
of GBS cases)a
Clinical features Refs
Classic sensorimotor 
GBSb
30–85 Rapidly progressive symmetrical weakness and sensory signs 
with absent or reduced tendon reflexes, usually reaching 
nadir within 2 weeks
11,24,114,115
Pure motorc 5–70 Motor weakness without sensory signs 5,11,24
Paraparetic 5–10 Paresis restricted to the legs 10,24,115
Pharyngeal–cervical–
brachial
<5 Weakness of pharyngeal, cervical and brachial muscles 
without lower limb weakness
10,114,115
Bilateral facial palsy 
with paraesthesiasd
<5 Bilateral facial weakness, paraesthesias and reduced reflexes 114–116
Pure sensoryd <1 Acute or subacute sensory neuropathy without other deficits 117,118
Miller Fisher syndrome 5–25 Ophthalmoplegia, ataxia and areflexia. Incomplete forms with 
isolated ataxia (acute ataxic neuropathy) or ophthalmoplegia 
(acute ophthalmoplegia) can occur31. Overlaps with classical 
sensorimotor GBS in an estimated 15% of patients
11,24,114,116–119
Bickerstaff brainstem 
encephalitisd
<5 Ophthalmoplegia, ataxia, areflexia, pyramidal tract signs 
and impaired consciousness, often overlapping with 
sensorimotor GBS
114,115
aEstimated frequencies, with percentages displayed to the nearest 5%, based on nine (primarily adult) cohort studies in various 
geographical regions10,11,24,114–119. Frequencies differ by region and study , contributing to the variability. Most studies are biased 
owing to exclusion of some of the variants. bThe sensorimotor form is seen in an estimated 70% of patients with GBS in Europe and 
the Americas, and in 30–40% of cases in Asia11. cThe pure motor variant is reported in 5–15% of patients with GBS in most studies, 
but in 70% cases in Bangladesh11,120. dDoes not fulfil commonly used diagnostic criteria for GBS, which require the presence of 
bilateral limb weakness or fulfilment of the criteria for Miller Fisher syndrome3,4. GBS, Guillain–Barré syndrome.
further studies showed a relationship between GBS 
and influenza vaccines45,46. These studies suggested 
an increase of approximately one additional GBS case 
per one million vaccinations, which is several orders 
of magni tude lower than that observed for the 1976 
influenza vaccine47,48. No other vaccines have been 
convincingly linked to GBS15.
A relationship between administration of immuno-
biologicals (for example, tumour necrosis factor antago-
nists, immune checkpoint inhibitors or type I interferons) 
and GBS has been reported on the basis of case series 
information and biological plausibility49. Other events, 
including but not limited to surgery and malignancy, have 
been temporally related to GBS, but these relationships 
lack a clear biological rationale and the epidemiological 
evidence is limited50,51.
Step 2: how to diagnose GBS
In the absence of sufficiently sensitive and specific 
disease biomarkers, the diagnosis of GBS is based on 
clinical history and examination, and is supported by 
ancillary investigations such as CSF examination and 
electrodiagnostic studies. The two most commonly used 
sets of diagnostic criteria for GBS were developed by the 
National Institute of Neurological Disorders and Stroke 
(NINDS) in 1978 (revised in 1990)2,3 (Box 1) and the 
Brighton Collaboration in 2011 (reF4) (Supplementary 
Table 1). Both sets of criteria were designed to investi-
gate the epidemiological association between GBS and 
vaccinations but have since been used in other clinical 
studies and trials. We consider the NINDS criteria to be 
more suited to the clinician as they present the clinical 
features of typical and atypical forms of GBS, although 
the criteria from the Brighton Collaboration are also 
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Box 1 | Diagnostic criteria for Guillain–Barré syndrome
This box lists the diagnostic criteria for Guillain–Barré syndrome (GBS) developed by 
the National Institute of Neurological Disorders and Stroke (NINDS)3 and subsequently 
modified in a review paper6. We have added some features that cast doubt on the 
diagnosis, which were not mentioned in the original criteria2,3,6, and have made some 
adaptations to improve readability. These criteria are not applicable to some of the 
specific variants of GBS, as described in TaBle 1.
Features required for diagnosis
•	Progressive bilateral weakness of arms and legs (initially only legs may be involved)a
•	Absent or decreased tendon reflexes in affected limbs (at some point in clinical course)a
Features that strongly support diagnosis
•	Progressive phase lasts from days to 4 weeks (usually <2 weeks)
•	Relative symmetry of symptoms and signs
•	Relatively mild sensory symptoms and signs (absent in pure motor variant)a
•	Cranial nerve involvement, especially bilateral facial palsya
•	Autonomic dysfunction
•	muscular or radicular back or limb painb
•	Increased protein level in cerebrospinal fluid (CSF); normal protein levels do not rule 
out the diagnosisb
•	electrodiagnostic features of motor or sensorimotor neuropathy (normal 
electrophysiology in the early stages does not rule out the diagnosis)b
Features that cast doubt on diagnosis
•	Increased numbers of mononuclear or polymorphonuclear cells in CSF (>50 × 106/l)
•	marked, persistent asymmetry of weakness
•	Bladder or bowel dysfunction at onset or persistent during disease courseb
•	Severe respiratory dysfunction with limited limb weakness at onsetb
•	Sensory signs with limited weakness at onseta
•	Fever at onset
•	Nadir <24 hb
•	Sharp sensory level indicating spinal cord injurya
•	Hyper- reflexia or clonusb
•	extensor plantar responsesb
•	Abdominal painb
•	Slow progression with limited weakness without respiratory involvement
•	Continued progression for >4 weeks after start of symptomsb
•	Alteration of consciousness (except in Bickerstaff brainstem encephalitis)b
minor adaptations were made by the authors to a simplified version of the original NINDS 
criteria6. aStatements in NINDS criteria that were adapted by authors to improve readability. 
bAdditional features which were not included in the NINDS. Note: for clarity, we have omitted 
‘Features that rule out the diagnosis’ from the original NINDS criteria for this adapted version.
important, widely used, and can help the clinician to 
classify cases with (typical) GBS or MFS according 
to diagnostic certainty. Various differential diagnoses 
must also be kept in mind when GBS is suspected, and 
some symptoms should raise suspicion of alternative 
diagnoses (Boxes 1 and 2). The role of ancillary investi-
gations in confirming a GBS diagnosis is described in 
more detail in the following section.
Laboratory investigations
Laboratory testing is guided by the differential diagno-
sis in individual patients, but in general all patients 
with suspected GBS will have complete blood counts 
and blood tests for glucose, electrolytes, kidney func-
tion and liver enzymes. Results of these tests can be 
used to exclude other causes of acute flaccid paralysis, 
such as infections or metabolic or electrolyte dysfunc-
tions (Box 2). Further specific tests may be carried out 
with the aim of excluding other diseases that can mimic 
GBS (Box 2). Testing for preceding infections does not 
usually contribute to the diagnosis of GBS, but can pro-
vide important epidemiological information during 
outbreaks of infectious diseases, as was seen in previ-
ous outbreaks of Zika virus and C. jejuni infection19,52. 
The diagnostic value of measuring serum levels of anti- 
ganglioside antibodies is limited and assay- dependent. 
A positive test result can be helpful, especially when the 
diagnosis is in doubt, but a negative test result does not 
rule out GBS53. Anti- GQ1b antibodies are found in up to 
90% of patients with MFS17,54 and therefore have greater 
diagnostic value in patients with suspected MFS than in 
patients with classic GBS or other variants. When GBS is 
suspected, we advise not to wait for antibody test results 
before starting treatment.
Cerebrospinal fluid examination
CSF examination is mainly used to rule out causes of 
weakness other than GBS and should be performed 
during the initial evaluation of the patient. The classic 
finding in GBS is the combination of an elevated CSF 
protein level and a normal CSF cell count (known as 
albumino- cytological dissociation)55. However, pro-
tein levels are normal in 30–50% of patients in the 
first week after disease onset and 10–30% of patients 
in the second week10,11,24,56. Therefore, normal CSF pro-
tein levels do not rule out a diagnosis of GBS. Marked 
pleocytosis (>50 cells/μl) suggests other pathologies, 
such as leptomeningeal malignancy or infectious or 
inflammatory diseases of the spinal cord or nerve roots. 
Mild pleocytosis (10–50 cells/μl), though compatible 
with GBS, should still prompt clinicians to consider 
alternative diagnoses, such as infectious causes of 
polyradiculitis10,11 (Box 2).
Electrodiagnostic studies
Electrodiagnostic studies are not required to diagnose 
GBS. However, we recommend that these studies are 
performed wherever possible as they are helpful in sup-
porting the diagnosis, particularly in patients with an 
atypical presentation. In general, electrophysiological 
examination in patients with GBS will reveal a sensori-
motor polyradiculoneuropathy or polyneuropathy, 
indicated by reduced conduction velocities, reduced sen-
sory and motor evoked amplitudes, abnormal temporal 
dispersion and/or partial motor conduction blocks6,57. 
Typical for GBS is a ‘sural sparing pattern’ in which the 
sural sensory nerve action potential is normal while 
the median and ulnar sensory nerve action potentials are 
abnormal or even absent6,57. However, electrophysiolog-
ical measurements might be normal when performed 
early in the disease course (within 1 week of symptom 
onset) or in patients with initially proximal weakness, 
mild disease, slow progression or clinical variants5,58,59. 
In these patients, a repeat electrodiagnostic study 
2–3 weeks later can be helpful. In patients with MFS, 
results of electrodiagnostic studies are usually normal or 
demonstrate only a reduced amplitude of sensory nerve 
action potentials4,60.
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Electrodiagnostic studies can also differentiate 
between the three electrophysiological subtypes of clas-
sical GBS: AIDP, AMAN, and AMSAN. Several sets 
of electrodiagnostic criteria exist that aim to classify 
patients into these different electrophysiological sub-
types on the basis of the presence of specific electro-
diagnostic characteristics in at least two motor nerves. 
International consensus is yet to be reached on which 
set of criteria best defines the electrophysiological sub-
types5,52,61. However, about one- third of patients with 
GBS do not meet any of these criteria and are labelled 
‘equivocal’ or ‘inexcitable’. Studies have demonstrated 
that repeating electrodiagnostic studies 3–8 weeks after 
disease onset might aid electrodiagnostic classification 
by allowing classification of cases that were initially 
unclassifiable, or reclassification of cases that were ini-
tially classified as AIDP, AMAN or AMSAN, although 
this practice is controversial62–64.
Imaging
MRI is not part of the routine diagnostic evaluation of 
GBS, but can be helpful, particularly for excluding differ-
ential diagnoses such as brainstem infection, stroke, spi-
nal cord or anterior horn cell inflammation, nerve root 
compression or leptomeningeal malignancy (Box 2). The 
presence of nerve root enhancement on gadolinium- 
enhanced MRI is a nonspecific but sensitive feature 
of GBS65 and can support a GBS diagnosis, especially 
in young children, in whom both clinical and electro-
physiological assessment can be challenging66. In light 
of recent outbreaks of acute flaccid myelitis in young 
children, the clinical presentation of which can mimic 
GBS, the potential use of MRI to distinguish between 
these two diagnoses should be given special attention67,68. 
However, clinicians should be mindful that nerve root 
enhancement can be found in a minority of individuals 
with acute flaccid myelitis69.
A new potential diagnostic tool in GBS is ultrasound 
imaging of the peripheral nerves, which has revealed 
enlarged cervical nerve roots early in the disease course, 
indicating the importance of spinal root inflammation 
as an early pathological mechanism70,71. This technique 
might, therefore, help establish a diagnosis of GBS early in 
the disease course, although further validation is required.
Step 3: when to admit to the ICU
Reasons to admit patients to the intensive care unit 
(ICU) include the following: evolving respiratory dis-
tress with imminent respiratory insufficiency, severe 
autonomic cardiovascular dysfunction (for example, 
arrhythmias or marked variation in blood pressure), 
severe swallowing dysfunction or diminished cough 
reflex, and rapid progression of weakness72,73. A state of 
imminent respiratory insufficiency is defined as clinical 
Box 2 | Differential diagnosis of Guillain–Barré syndrome
The differential diagnosis of Guillain–Barré syndrome is broad and highly 
dependent on the clinical features of the individual patient. Here, we 
present an overview of the most important differential diagnoses 
categorized by location in the nervous system.
CNS
•	Inflammation or infection of the brainstem (for example, sarcoidosis, 
Sjögren syndrome, neuromyelitis optica or myelin oligodendrocyte 
glycoprotein antibody- associated disorder)a
•	Inflammation or infection of the spinal cord (for example, sarcoidosis, 
Sjögren syndrome or acute transverse myelitis)
•	malignancy (for example, leptomeningeal metastases or 
neurolymphomatosis)
•	Compression of brainstem or spinal cord
•	Brainstem stroke
•	vitamin deficiency (for example, Wernicke encephalopathya, caused  
by deficiency of vitamin B1, or subacute combined degeneration of  
the spinal cord, caused by deficiency of vitamin B12)
Anterior horn cells
•	Acute flaccid myelitis (for example, as a result of polio, enterovirus  
D68 or A71, West Nile virus, Japanese encephalitis virus or rabies  
virus)
Nerve roots
•	Infection (for example, lyme disease, cytomegalovirus, HIv, epstein–
Barr virus or varicella zoster virus)
•	Compression
•	leptomeningeal malignancy
Peripheral nerves
•	Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
•	metabolic or electrolyte disorders (for example, hypoglycaemia, 
hypothyroidism, porphyria or copper deficiency)
•	vitamin deficiency (for example, deficiency of vitamins B1 (also known 
as beriberi), B12 or e)
•	Toxins (for example, drugs, alcohol, vitamin B6, lead, thallium, arsenic, 
organophosphate, ethylene glycol, diethylene glycol, methanol or 
N- hexane)
•	Critical illness polyneuropathy
•	Neuralgic amyotrophy
•	vasculitis
•	Infection (for example, diphtheria or HIv)
Neuromuscular junction
•	myasthenia gravis
•	lambert–eaton myasthenic syndrome
•	Neurotoxins (for example, botulism, tetanus, tick paralysis or snakebite 
envenomation)
•	organophosphate intoxication
Muscles
•	metabolic or electrolyte disorders (for example, hypokalaemia, 
thyrotoxic hypokalaemic periodic paralysis, hypomagnesaemia or 
hypophosphataemia)
•	Inflammatory myositis
•	Acute rhabdomyolysis
•	Drug- induced toxic myopathy (for example, induced by colchicine, 
chloroquine, emetine or statins)
•	mitochondrial disease
Other
•	Conversion or functional disorder
aDifferential diagnosis for Bickerstaff brainstem encephalitis.
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Box 3 | Erasmus GBS Respiratory Insufficiency Score
The erasmus Guillain–Barré syndrome (GBS) Respiratory Insufficiency Score (eGRIS) 
calculates the probability that a patient with GBS will require mechanical ventilation 
within 1 week of assessment and is based on three key measures. each measure is 
categorized and assigned an individual score; the sum of these scores gives an overall 
eGRIS for that patient (between 0 and 7). An eGRIS of 0–2 indicates a low risk of 
mechanical intervention (4%), 3–4 indicates an intermediate risk of mechanical 
intervention (24%) and ≥5 indicates a high risk of mechanical intervention (65%). This 
model is based on a Dutch population of patients with GBS (aged >6 years) and has not 
yet been validated internationally. Therefore, it may not be applicable in other age 
groups or populations. An online resource that automatically calculates the eGRIS for a 
patient based on answers to a series of questions has been made available by the 
International GBS outcome Study (IGoS) consortium (see Related links). The medical 
Research Council (mRC) sum score is the sum of the score on the mRC scale for: muscle 
weakness of bilateral shoulder abduction; elbow flexion; wrist extension; hip flexion; 
knee extension; and ankle dorsiflexion. A higher mRC sum score denotes increased 
disability, up to a maximum score of 60.
NA, not applicable. Adapted with permission from reF.74, Wiley- vCH.
Measure Categories Score
Days between onset of weakness and hospital admission >7 days 0
4–7 days 1
≤3 days 2
Facial and/or bulbar weakness at hospital admission Absent 0
Present 1
MRC sum score at hospital admission 60–51 0
50–41 1
40–31 2
30–21 3
≤20 4
EGRIS NA 0–7
signs of respiratory distress, including breathlessness at 
rest or during talking, inability to count to 15 in a single 
breath, use of accessory respiratory muscles, increased 
respiratory or heart rate, vital capacity <15–20 ml/kg or 
<1 l, or abnormal arterial blood gas or pulse oximetry 
measurements.
As up to 22% of patients with GBS require mechanical 
ventilation within the first week of admission, patients at 
risk of respiratory failure must be identified as early as 
possible74. The Erasmus GBS Respiratory Insufficiency 
Score (EGRIS) prognostic tool was developed for this 
purpose and calculates the probability (1–90%) that 
a patient will require ventilation within 1 week of 
assessment74 (Box 3).
Risk factors for prolonged mechanical ventilation 
include the inability to lift the arms from the bed at 
1 week after intubation, and an axonal subtype or unex-
citable nerves in electrophysiological studies75. Early tra-
cheostomy should be considered in patients who have 
these risk factors.
Step 4: when to start treatment
Immunomodulatory therapy should be started if 
patients are unable to walk independently for 10 m 
(reFs76,77). Evidence on treatment efficacy in patients 
who can still walk independently is limited, but treat-
ment should be considered, especially if these patients 
display rapidly progressive weakness or other severe 
symptoms such as autonomic dysfunction, bulbar 
failure or respiratory insufficiency78–80. Clinical trials 
have demonstrated a treatment effect for intravenous 
immunoglobu lin (IVIg) when started within 2 weeks of 
the onset of weakness and for plasma exchange when 
started within 4 weeks76,77. Beyond these time periods, 
evidence on efficacy is lacking.
Step 5: treatment options
Treatment strategies
IVIg (0.4 g/kg body weight daily for 5 days) and plasma 
exchange (200–250 ml plasma/kg body weight in five 
sessions) are equally effective treatments for GBS76,80. 
IVIg and plasma exchange carry comparable risks of 
adverse events, although early studies showed that 
plasma exchange was more likely than IVIg to be dis-
continued76,81. As IVIg is also easier to administer and 
generally more widely available than plasma exchange, 
it is usually the treatment of choice. Besides IVIg and 
plasma exchange, no other procedures or drugs have 
been proven effective in the treatment of GBS. Although 
corticosteroids would be expected to be beneficial in 
reducing inflammation and, therefore, disease progres-
sion in GBS, eight randomized controlled trials on the 
efficacy of corticosteroids for GBS showed no signifi-
cant benefit, and treatment with oral corticosteroids 
was even shown to have a negative effect on outcome82. 
Furthermore, plasma exchange followed by IVIg is no 
more effective than either treatment alone and insuf-
ficient evidence is available for the efficacy of add- on 
treatment with intravenous methylprednisolone in IVIg- 
treated patients82,83. In clinical settings where resources 
are limited, small- volume plasma exchange might be 
an economical and relatively safe alternative to conven-
tional plasma exchange, but this approach cannot be 
recommended for general use until its efficacy has been 
established in further trials84.
Antimicrobial or antiviral treatment can be consid-
ered in patients with GBS who have an ongoing infec-
tion; however, preceding infections have usually resolved 
before the onset of weakness.
Specific patient groups
GBS variants. Patients with pure MFS tend to have a 
relatively mild disease course, and most recover com-
pletely without treatment within 6 months85. Therefore, 
treatment is generally not recommended in this patient 
group but patients should be monitored closely because 
a subgroup can develop limb weakness, bulbar or facial 
palsy, or respiratory failure32,80. The severity of the dis-
ease course of BBE justifies treatment with IVIg or 
plasma exchange, although evidence for the efficacy 
of treatment in this context is limited34,85. For the other 
clinical variants, no evidence regarding treatment is cur-
rently available, although many experts will administer 
IVIg or plasma exchange86.
Pregnant women. Neither IVIg nor plasma exchange 
is contraindicated during pregnancy. However, as 
plasma exchange requires additional considerations 
and monitoring, IVIg might be preferred87–89.
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Children. There is no indication that it is necessary to 
deviate from standard adult practice when treating chil-
dren with GBS76,78,90. Evidence on the relative efficacies 
of plasma exchange and IVIg in children is limited90. 
However, as plasma exchange is only available in centres 
that are experienced with its use and seems to produce 
greater discomfort and higher rates of complications than 
IVIg in children, IVIg is usually the first- line therapy for 
children with GBS91. Although some paediatric centres 
administer IVIg as 2 g/kg (body weight) over 2 days, 
rather than the standard adult regimen of 2 g/kg (body 
weight) over 5 days, one study indicated that TRFs were 
more frequent with a 2-day regimen (5 of 23 children) 
than with the 5-day regimen (0 of 23 children)78.
Step 6: monitoring disease progression
Regular assessment is required to monitor disease pro-
gression and the occurrence of complications. First, rou-
tine measurement of respiratory function is advised, as 
not all patients with respiratory insufficiency will have 
clinical signs of dyspnoea. These respiratory measure-
ments can include usage of accessory respiratory mus-
cles, counting during expiration of one full- capacity 
inspiratory breath (a single breath count of ≤19 predicts 
a requirement for mechanical ventilation), vital capacity, 
and maximum inspiratory and expiratory pressure73,92. 
Clinicians should consider using the ‘20/30/40 rule’, 
whereby the patient is deemed at risk of respiratory fail-
ure if the vital capacity is <20 ml/kg, the maximum inspir-
atory pressure is <30 cmH2O or the maximum expiratory 
pressure is <40 cmH2O (reF93). Second, muscle strength 
in the neck, arms and legs should be assessed using 
the Medical Research Council grading scale or a simi-
lar scale, and functional disability should be assessed 
on the GBS disability scale (Supplementary Table 2), a 
widely used tool for documenting GBS disease course94. 
Third, patients should be monitored for swallowing 
and coughing difficulties. Last, autonomic dysfunc-
tion should be assessed via electrocardiography and 
monitoring of heart rate, blood pressure, and bowel 
and bladder function.
The nature and frequency of monitoring depends 
on the rate of deterioration, the presence or absence of 
autonomic dysfunction, the phase of the disease, and the 
healthcare setting, and should be carefully assessed in 
each individual patient. Up to two- thirds of the deaths 
of patients with GBS occur during the recovery phase 
and are mostly caused by cardiovascular and respira-
tory dysfunction6,7,11. We therefore advise clinicians to 
stay alert during this phase and monitor the patient for 
potential arrhythmias, blood pressure shifts, or respira-
tory distress caused by mucus plugs. This monitoring is 
especially important in patients who have recently left 
the ICU and in those with cardiovascular risk factors.
Step 7: managing early complications
Complications in GBS can cause severe morbidity and 
death95. Some of these complications, including pres-
sure ulcers, hospital- acquired infections (for example, 
pneumonia or urinary tract infections) and deep vein 
thrombosis, can occur in any hospitalized bed- bound 
patient, and standard- practice preventive measures and 
treatment are recommended. Other complications are 
more specific to GBS, for example, the inability to swal-
low safely in patients with bulbar palsy; corneal ulcera-
tion in patients with facial palsy; and limb contractures, 
ossification and pressure palsies in patients with limb 
weakness (TaBle 2). Pain, hallucinations, anxiety and 
depression are also frequent in patients with GBS, 
and care givers should specifically ask patients whether they 
are experiencing these symptoms, especially if patients 
have limited communication abilities and/or are in the 
ICU. Recognition and adequate treatment of psycho-
logical symptoms and pain at an early stage is impor-
tant because these symptoms can have a major impact 
on the wellbeing of patients. Caregivers should also be 
aware that patients with GBS, even those with complete 
paralysis, usually have intact consciousness, vision and 
hearing. It is important, therefore, to be mindful of 
what is said at the bedside, and to explain the nature 
of procedures to patients to reduce anxiety. Adequate 
management of complications is best undertaken by a 
multidisciplinary team, which might include nurses, 
physiotherapists, rehabilitation specialists, occupational 
therapists, speech therapists and dietitians.
Step 8: managing clinical progression
Insufficient response to treatment
About 40% of patients treated with standard doses of 
plasma exchange or IVIg do not improve in the first 
4 weeks following treatment80,82. Such disease progres-
sion does not imply that the treatment is ineffective, 
as progression might have been worse without ther-
apy6. Clinicians may consider repeating the treatment 
or changing to an alternative treatment, but at present 
no evidence exists that this approach will improve the 
outcome96,97. A clinical trial investigating the effect of 
administering a second IVIg dose is ongoing98.
Table 2 | Important complications of Guillain–Barré syndrome
Complication When to be alert
Choking Bulbar palsy
Cardiac arrhythmias All patients
Hospital- acquired infections  
(e.g., pneumonia, sepsis or urinary 
tract infection)
Bulbar and facial palsy , immobility , bladder 
dysfunction, mechanical ventilation
Pain and tactile allodynia Limited communication
Delirium Limited communication
Depression Limited communication
Urinary retention All patients
Constipation Immobility
Corneal ulceration Facial palsy
Dietary deficiency Bulbar and facial palsy
Hyponatraemia All patients
Pressure ulcers Immobility
Compression neuropathy Immobility
Limb contractures and ossifications Severe weakness for prolonged period of time
Important complications of Guillain–Barré syndrome (GBS)72. Most of these complications can 
occur in any patient with GBS, at any time, but the second column shows when they are most 
likely to occur and/or when to be especially alert.
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Treatment- related fluctuations
TRFs are observed in 6–10% of patients with GBS and are 
defined as disease progression occurring within 2 months 
following an initial treatment- induced clinical improve-
ment or stabilization12,13. TRFs should be distinguished 
from clinical progression without any initial response 
to treatment. The general view is that a TRF indicates 
that the treatment effect has worn off while the inflam-
matory phase of the disease is still ongoing. Therefore, 
patients with GBS who display TRFs might benefit from 
further treatment, and repeating the full course of IVIg or 
plasma exchange in these patients is a common practice, 
although evidence to support this approach is lacking80.
CIDP
In ~5% of patients with GBS, repeated clinical relapses 
suggest a more chronic disease process, and the diagno-
sis is changed to acute- onset CIDP12. Acute- onset CIDP 
typi cally presents with three or more TRFs and/or clinical 
deterioration ≥8 weeks after disease onset12.
Step 9: predicting outcome
Most patients with GBS, even those who were tetraplegic 
at nadir or required mechanical ventilation for a long 
period of time, show extensive recovery, especially in the 
first year after disease onset11,99. About 80% of patients 
with GBS regain the ability to walk independently at 
6 months after disease onset11. The probability of regain-
ing walking ability can be calculated in individual 
patients using the modified Erasmus GBS outcome score 
(mEGOS) prognostic tool100 (Supplementary Table 3).
Despite the generally positive prospects for patients 
with GBS, death occurs in 3–10% of cases, most commonly 
owing to cardiovascular and respiratory compli cations, 
which can occur in both the acute and the recovery 
phase7–9. Risk factors for mortality include advanced age 
and severe disease at onset7. Long-term residual com-
plaints are also common and can include neuropathic 
pain, weakness and fatigue101–103. However, recovery 
from these complaints may still occur >5 years after 
disease onset103.
Recurrent episodes of GBS are rare, affecting 2–5% 
of patients, but this percentage is still higher than the 
lifetime risk of GBS in the general population (0.1%)14,15. 
Many vaccines carry a warning about GBS, although 
prior GBS is not a strict contraindication for vaccination. 
Discussion with experts might be useful for patients who 
were diagnosed with GBS <1 year before a planned vac-
cination or who previously developed GBS shortly after 
receiving the same vaccination. In these patients, the 
benefits of vaccination for specific illnesses (for exam-
ple, influenza in elderly individuals) must be weighed 
against the small and possibly only theoretical risk of a 
recurrent GBS episode14.
Step 10: planning rehabilitation
Patients with GBS can experience a range of long- term 
residual problems, including incomplete recovery of 
motor and sensory function, as well as fatigue, pain and 
psychological distress103. Before the patient is dis charged, 
these possible long- term effects of GBS should be 
considered and managed104,105.
Physical function
Arranging a rehabilitation programme with a rehabili-
tation specialist, physiotherapist and occupational thera-
pist is a crucial step towards recovery. Programmes 
should aim to reduce disability in the early stages of 
recovery and later to restore motor and sensory function 
and physical condition to predisease levels106. Exercise 
programmes for patients with GBS, which include range- 
of-motion exercises, stationary cycling, and walking and 
strength training, have been shown to improve physical 
fitness, walking ability and independence in activities of 
daily living106. However, the intensity of exercise must 
be closely monitored as overwork can cause fatigue106.
Fatigue
Fatigue, unrelated to residual motor deficits, is found 
in 60–80% of patients with GBS and is often one of the 
most disabling complaints107,108. Other causes should be 
considered before concluding that fatigue in a patient 
is a residual result of GBS. As with recovery of physical 
function, a graded, supervised exercise programme has 
been shown to be useful in reducing fatigue109.
Pain
Severe pain is reported in at least one- third of patients 
with GBS 1 year after disease onset and can persist for 
>10 years14,26. Chronic pain in GBS is characterized by 
muscle pain in the lower back and limbs, painful par-
aesthesias, arthralgia, and radicular pain. Although the 
pathogenesis of this pain is not fully understood, muscle 
pain and arthralgia might be attributable to immobil-
ity, and neuropathic pain might be caused by regener-
ation of, or persistent damage to, small nerve fibres26. 
Management strategies include encouraging mobi-
lization and administering drugs for neuropathic or 
nociceptive pain104.
Psychological distress
Rapid loss of physical function, often in previously 
healthy individuals, can be severely traumatic and may 
cause anxiety and/or depression. Early recognition and 
management of psychological distress is important 
in patients with GBS, especially as mental status can 
influence physical recovery and vice versa; referral to 
a psychologist or psychiatrist might be beneficial for 
some patients110. Providing accurate information to 
patients on the relatively good chance of recovery and 
low recurrence risk (2–5%) can help reduce their fear11,14. 
Connecting patients with others who have had GBS can 
also help guide them through the rehabilitation process. 
The GBS/CIDP Foundation International — the interna-
tional patient association for GBS — and other national 
organizations can help establish these networks.
Conclusions
GBS can be a complex disorder to diagnose and man-
age as the clinical presentation is heterogeneous and the 
prognosis varies widely between patients. Managing 
GBS can be especially challenging during outbreaks 
triggered by infectious disease, as was most recently 
seen during the Zika virus epidemic. In the absence 
of an international clinical guideline for GBS, we have 
680 | NovemBeR 2019 | volume 15 www.nature.com/nrneurol
C o n S e n S u S  S tat e m e n t
developed this consensus guideline for the diagnosis 
and management of GBS. This guideline was developed 
by a team of clinical neurologists from around the world 
and is designed for general applicability in all clinical 
environments, irrespective of specialist capabilities or 
availability of resources. The step- by-step design was 
used to focus attention on the most important issues 
in GBS and to make the guideline easy to use in clinical 
practice.
As the field of GBS research develops, and ongoing 
studies aim to improve diagnostics, treatment and prog-
nostic modelling, this guideline will need to be updated 
regularly. For example, ultrasound imaging of the 
peripheral nerves is emerging as a potential diagnostic 
tool and might require further comment in future ver-
sions of this guideline. In relation to treatment, the effi-
cacy of complement inhibitors, IgG- cleaving enzymes 
and a second course of IVIg is being investigated78,111,112. 
Little is known about how to measure and predict long- 
term outcome in patients with GBS, and validation stud-
ies of known prognostic models (for example, mEGOS 
and EGRIS) and research into new outcome measures 
are needed. We intend to seek feedback on this guide-
line and provide updates based on results from ongoing 
studies and future research.
To further improve the worldwide management of 
GBS, we aim to use this consensus report as a basis for 
the development of online information resources, train-
ing material and teaching courses. These resources will 
be directed towards healthcare workers, including 
clinical neurologists, as well as patients with GBS and 
their relatives.
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